Search results
Results from the WOW.Com Content Network
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. [1] Their use can prevent some cases of pneumonia, meningitis, and sepsis. [1] There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. [1] They are given by injection either into a muscle or just under the skin. [1]
In epidemiology, seroconversion is often used in reference to observing the evolution of a virus from a host or natural reservoir host to the human population. Epidemiologists compare archived human blood specimens taken from infected hosts before an epidemic and later specimens from infected hosts at later stages of the epidemic.
Cows are natural reservoirs of African trypanosomiasis. In infectious disease ecology and epidemiology, a natural reservoir, also known as a disease reservoir or a reservoir of infection, is the population of organisms or the specific environment in which an infectious pathogen naturally lives and reproduces, or upon which the pathogen primarily depends for its survival.
The black rat is a reservoir host for bubonic plague. The rat fleas that infest the rats are vectors for the disease. In biology and medicine, a host is a larger organism that harbours a smaller organism; [1] whether a parasitic, a mutualistic, or a commensalist guest . The guest is typically provided with nourishment and shelter.
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).
As of 2023, development of a reliable antiviral therapy treatment or vaccine to prevent the spread of hMPV has yet to occur, but there does seem to be promising developments in that area. [ 4 ] [ 5 ] In some vaccine trials, researchers have observed how a live recombinant human parainfluenza virus that contains the hMPV F gene can induce hMPV ...